| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Priority Reports |
1 1Genetics Branch and 2Laboratory of Pathology, NIH/National Cancer Institute; 3Pathology Department, Suburban Hospital, Bethesda, Maryland; 4Illumina, Inc., San Diego, California; and 5School of Medicine, University of California-San Francisco, San Francisco, California
* To whom correspondence should be addressed. E-mail: pmeltzer{at}mail.nih.gov.
| Abstract |
|---|
Emerging technologies allow broad profiling of the cancer genome for differential DNA methylation relative to benign cells. Herein, bisulfite-modified DNA from lymph nodes with either reactive hyperplasia or follicular lymphoma (FL) were analyzed using a commercial C/UpG genotyping assay. Two hundred fifty-nine differentially methylated targets (DMT) distributed among 183 unique genes were identified in FL. Comparison of matched formalin-fixed, paraffin-embedded and frozen surgical pathology replicates showed the complete preservation of the cancer methylome among differently archived tissue specimens. Analysis of the DMT profile is consistent with a pervasive epigenomic remodeling process in FL that affects predominantly nonlymphoid genes. [Cancer Res 2009;69(3):758–64]
Key Words: follicular lymphoma, methylation profiling, epigenetics, FFPE, pathology
This article has been cited by other articles:
![]() |
S. Vikman, R. M. Brena, P. Armstrong, J. Hartiala, C. B. Stephensen, and H. Allayee Functional analysis of 5-lipoxygenase promoter repeat variants Hum. Mol. Genet., December 1, 2009; 18(23): 4521 - 4529. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |